Safety profile of BCG with or without immunotherapy in non–muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis
Background Intravesical bacillus Calmette-Guérin (BCG) is the standard of care for BCG-naïve high-risk non–muscle-invasive bladder cancer (NMIBC). Recent phase III trials showed reduced disease recurrence with the addition of immune checkpoint inhibitors (ICIs) to BCG induction plus maintenance but with increased toxic...